Geza Bodor
Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tandem Mass Spectrometry | 3 | 2024 | 411 | 1.140 |
Why?
| Troponin I | 8 | 2017 | 68 | 0.960 |
Why?
| Anticonvulsants | 1 | 2024 | 179 | 0.780 |
Why?
| Drug Monitoring | 2 | 2024 | 184 | 0.760 |
Why?
| Chromatography, Liquid | 2 | 2024 | 347 | 0.740 |
Why?
| Epilepsy | 1 | 2024 | 277 | 0.680 |
Why?
| Analgesics, Opioid | 2 | 2018 | 771 | 0.680 |
Why?
| Substance Abuse Detection | 3 | 2018 | 62 | 0.670 |
Why?
| Clinical Chemistry Tests | 2 | 2018 | 9 | 0.640 |
Why?
| Troponin T | 3 | 2017 | 49 | 0.630 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 87 | 0.580 |
Why?
| Troponin | 6 | 1998 | 44 | 0.580 |
Why?
| Aviation | 1 | 2016 | 9 | 0.540 |
Why?
| Chemistry, Clinical | 1 | 2016 | 11 | 0.540 |
Why?
| Myocardial Infarction | 5 | 2017 | 927 | 0.530 |
Why?
| Thrombin | 1 | 2017 | 139 | 0.530 |
Why?
| Professional Competence | 1 | 2016 | 81 | 0.520 |
Why?
| Mass Spectrometry | 2 | 2018 | 633 | 0.510 |
Why?
| Thyrotropin | 1 | 2014 | 99 | 0.460 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2016 | 470 | 0.460 |
Why?
| Clinical Decision-Making | 1 | 2016 | 268 | 0.450 |
Why?
| Hyponatremia | 1 | 2013 | 37 | 0.420 |
Why?
| Carcinoma | 1 | 2014 | 198 | 0.420 |
Why?
| Thyroid Neoplasms | 1 | 2014 | 264 | 0.380 |
Why?
| Myocardium | 7 | 2017 | 913 | 0.360 |
Why?
| Decision Making | 1 | 2016 | 782 | 0.340 |
Why?
| Neoplasm Recurrence, Local | 1 | 2014 | 858 | 0.330 |
Why?
| Schizophrenia | 1 | 2013 | 414 | 0.320 |
Why?
| Immunoassay | 3 | 2018 | 95 | 0.270 |
Why?
| Pentobarbital | 1 | 2024 | 16 | 0.230 |
Why?
| Humans | 20 | 2024 | 114654 | 0.170 |
Why?
| Muscular Dystrophies | 2 | 1997 | 36 | 0.170 |
Why?
| False Positive Reactions | 3 | 2014 | 109 | 0.150 |
Why?
| Muscle, Skeletal | 2 | 1997 | 1472 | 0.140 |
Why?
| False Negative Reactions | 1 | 2017 | 48 | 0.140 |
Why?
| Accidents, Aviation | 1 | 2016 | 4 | 0.140 |
Why?
| Decision Making, Computer-Assisted | 1 | 2016 | 18 | 0.140 |
Why?
| Pain Management | 1 | 2018 | 288 | 0.130 |
Why?
| Iodine Radioisotopes | 1 | 2014 | 125 | 0.110 |
Why?
| Carcinoma, Papillary | 1 | 2014 | 73 | 0.110 |
Why?
| Chromatography, Affinity | 1 | 1992 | 80 | 0.100 |
Why?
| Radiography | 1 | 2014 | 812 | 0.100 |
Why?
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1991 | 5 | 0.100 |
Why?
| Laboratories | 1 | 1992 | 95 | 0.100 |
Why?
| Fetus | 1 | 1995 | 700 | 0.100 |
Why?
| Liver Diseases | 1 | 1991 | 255 | 0.080 |
Why?
| Cocaine | 1 | 1990 | 153 | 0.070 |
Why?
| Middle Aged | 5 | 2017 | 26732 | 0.070 |
Why?
| Antigens, Neoplasm | 1 | 1989 | 222 | 0.070 |
Why?
| Ovarian Neoplasms | 1 | 1991 | 388 | 0.070 |
Why?
| Polymyositis | 2 | 1997 | 15 | 0.070 |
Why?
| Antibodies, Monoclonal | 1 | 1992 | 1262 | 0.070 |
Why?
| Creatine Kinase | 3 | 1995 | 75 | 0.070 |
Why?
| Reference Standards | 3 | 2006 | 159 | 0.060 |
Why?
| Antibody Specificity | 2 | 1997 | 176 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 1997 | 797 | 0.050 |
Why?
| Quality Control | 2 | 1992 | 144 | 0.050 |
Why?
| Reference Values | 2 | 1992 | 743 | 0.050 |
Why?
| Male | 5 | 2014 | 55579 | 0.040 |
Why?
| Biomarkers | 3 | 1998 | 3408 | 0.040 |
Why?
| Chromatography, Gel | 1 | 1998 | 122 | 0.040 |
Why?
| Reagent Kits, Diagnostic | 1 | 1998 | 42 | 0.040 |
Why?
| Neoplasms | 1 | 1991 | 2097 | 0.040 |
Why?
| Cross Reactions | 1 | 1997 | 117 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 1997 | 192 | 0.030 |
Why?
| Female | 5 | 2017 | 59488 | 0.030 |
Why?
| Regeneration | 1 | 1997 | 160 | 0.030 |
Why?
| Blotting, Western | 1 | 1997 | 1147 | 0.030 |
Why?
| Clinical Enzyme Tests | 1 | 1993 | 11 | 0.030 |
Why?
| Indicators and Reagents | 1 | 1992 | 99 | 0.030 |
Why?
| Muscular Diseases | 1 | 1993 | 104 | 0.030 |
Why?
| Binding, Competitive | 1 | 1992 | 193 | 0.030 |
Why?
| Hybridomas | 1 | 1992 | 230 | 0.030 |
Why?
| Immunoblotting | 1 | 1992 | 283 | 0.020 |
Why?
| Dogs | 1 | 1992 | 334 | 0.020 |
Why?
| Immunohistochemistry | 1 | 1995 | 1629 | 0.020 |
Why?
| Rabbits | 1 | 1992 | 733 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 1993 | 1342 | 0.020 |
Why?
| Cattle | 1 | 1992 | 921 | 0.020 |
Why?
| Immunologic Techniques | 1 | 1989 | 39 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 1992 | 1982 | 0.020 |
Why?
| Immunoglobulin G | 1 | 1992 | 770 | 0.020 |
Why?
| Prostate-Specific Antigen | 1 | 1989 | 151 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 1993 | 489 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 1992 | 2785 | 0.020 |
Why?
| Analysis of Variance | 1 | 1990 | 1226 | 0.020 |
Why?
| Troponin C | 1 | 2006 | 5 | 0.020 |
Why?
| Calibration | 1 | 2006 | 125 | 0.020 |
Why?
| Adult | 3 | 1995 | 30542 | 0.010 |
Why?
| Pregnancy | 1 | 1995 | 5517 | 0.010 |
Why?
| Postoperative Complications | 1 | 1994 | 2128 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2006 | 1230 | 0.010 |
Why?
| Biomarkers, Tumor | 1 | 1989 | 1040 | 0.010 |
Why?
| Adenocarcinoma | 1 | 1989 | 795 | 0.010 |
Why?
| Prostatic Neoplasms | 1 | 1989 | 921 | 0.010 |
Why?
| Sensitivity and Specificity | 2 | 1994 | 1691 | 0.010 |
Why?
| Regression Analysis | 1 | 2001 | 944 | 0.010 |
Why?
| Mice | 1 | 1992 | 14863 | 0.010 |
Why?
| Retrospective Studies | 1 | 1992 | 12544 | 0.010 |
Why?
| Algorithms | 1 | 2001 | 1467 | 0.010 |
Why?
| Isoenzymes | 1 | 1993 | 283 | 0.010 |
Why?
| Muscles | 1 | 1993 | 320 | 0.010 |
Why?
| Animals | 1 | 1992 | 31698 | 0.010 |
Why?
| Vascular Surgical Procedures | 1 | 1994 | 259 | 0.010 |
Why?
| Running | 1 | 1993 | 207 | 0.010 |
Why?
| Incidence | 1 | 1994 | 2312 | 0.000 |
Why?
| Risk Factors | 1 | 1994 | 8631 | 0.000 |
Why?
|
|
Bodor's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|